Search

Your search keyword '"Merck & Company Inc. -- Product development"' showing total 2,478 results
Start Over Descriptor "Merck & Company Inc. -- Product development"
2,478 results on '"Merck & Company Inc. -- Product development"'

1. PMV provides update on Phase 2, Phase 1b portions of PYNNACLE trial

Subjects
Merck & Company Inc. -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Business, News, opinion and commentary
Abstract

PMV Pharmaceuticals (PMVP) provided an update on the Phase 2 monotherapy and Phase 1b combination portions of the ongoing PYNNACLE clinical trial. Enrollment on track in registrational Phase 2 portion [...]

Published
2024

2. Merck reports 'positive' results from Phase 2b/3 trial of clesrovimab

Subjects
Merck & Company Inc. -- Product development, Contraceptives industry -- Product development, Clinical trials, Monoclonal antibodies, Pharmaceutical industry -- Product development, Business, News, opinion and commentary
Abstract

Merck announced the presentation of positive results from the Phase 2b/3 clinical trial evaluating clesrovimab, the company's investigational prophylactic monoclonal antibody designed to protect infants from respiratory syncytial virus disease [...]

Published
2024

3. Kineta announces completion of enrollment in monotherapy arm of VISTA-101

Subjects
Merck & Company Inc. -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Business, News, opinion and commentary
Abstract

Kineta (KA) announced that it has completed the enrollment of new patients into the monotherapy arm of the VISTA-101 phase 1 clinical trial evaluating KVA12123, Kineta's novel VISTA blocking immunotherapy, [...]

Published
2024

5. Cytovation to present safety and efficacy data from CICILIA phase I/IIa clinical trial evaluating CY-101 in solid tumors

Subjects
Merck & Company Inc. -- Product development, Tumors, Clinical trials, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries
Abstract

Cytovation ASA, a clinical stage oncology company focused on the development of its first-in-class bifunctional immunotherapy CY-101 (CyPep-1) announced that it will deliver a poster presentation at ESMO 2024 entitled [...]

Published
2024

6. BeyondSpring presented interim Phase 2 data on 303 Study

Subjects
Merck & Company Inc. -- Product development, Development and progression, Product development, Chemotherapy, Pharmaceutical industry -- Product development, Non-small cell lung cancer -- Development and progression, Lung cancer, Non-small cell -- Development and progression, Cancer -- Chemotherapy
Abstract

BeyondSpring (BYSI) presented interim phase 2 data on the 303 Study, a study in 2L/3L non-small cell lung cancer, NSCLC, after disease progression on 1L PD-1/L1 inhibitors with and without [...]

Published
2024

7. Merck announces long-term OS data from pivotal Phase 3 KEYNOTE-006 trial

Subjects
Merck & Company Inc. -- Product development, Operating systems -- Product development, Ipilimumab, Clinical trials, Melanoma -- Care and treatment, Pharmaceutical industry -- Product development, 64-bit operating system, 32-bit operating system, Operating system, Business, News, opinion and commentary, Keytruda (Medication) -- Product development
Abstract

Merck announced long-term overall survival data from the pivotal Phase 3 KEYNOTE-006 trial, evaluating KEYTRUDA, Merck's anti-PD-1 therapy, in patients with advanced melanoma. Based on 10 years of follow-up, the [...]

Published
2024

8. Merck announces OS results from pivotal Phase 3 KEYNOTE-A18 trial

Subjects
Merck & Company Inc. -- Product development, Cervical cancer -- Care and treatment, Pharmaceutical industry -- Product development, Business, News, opinion and commentary, Keytruda (Medication) -- Product development
Abstract

Merck announced the first presentation of overall survival results from the pivotal Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with concurrent chemoradiotherapy [...]

Published
2024

9. IO Biotech announces results from Phase 2 trial of IO102-IO103

Subjects
Merck & Company Inc. -- Product development, Biotechnology, Squamous cell carcinoma, Clinical trials, Vaccines -- Product development, Pharmaceutical industry -- Product development, Business, News, opinion and commentary
Abstract

IO Biotech (IOBT) announced promising data from the Phase 2 basket trial of IO102-IO103, the company's lead investigational therapeutic cancer vaccine candidate, in combination with Merck's (MRK) anti-PD-1 therapy KEYTRUDA [...]

Published
2024

10. Merck, EyeBio initiate phase 2b/3 trial for Restoret to treat diabetic macular edema

Subjects
Merck & Company Inc. -- Product development, Care and treatment, Product development, Clinical trials, Macular degeneration -- Care and treatment, Pharmaceutical industry -- Product development, Edema -- Care and treatment, Dropsy -- Care and treatment
Abstract

Merck, known as MSD outside of the United States and Canada, and EyeBio, a wholly-owned subsidiary of Merck & Co., Inc., Rahway, New Jersey, USA, announced the initiation of the [...]

Published
2024

11. Merck begins Phase 2b/3 of the BRUNELLO trial

Subjects
Merck & Company Inc. -- Product development, Macular degeneration, Clinical trials, Pharmaceutical industry -- Product development, Business, News, opinion and commentary
Abstract

Merck and EyeBio, a wholly-owned subsidiary of Merck & Co., announced the initiation of the Phase 2b/3 BRUNELLO trial evaluating Restoret MK-3000, formerly EYE103, for the treatment of diabetic macular [...]

Published
2024

12. Merck initiates Phase 3 trial of bomedemstat

Subjects
Merck & Company Inc. -- Product development, Product development, Clinical trials, Pharmaceutical industry -- Product development
Abstract

Merck announced the initiation of Shorespan-007, a pivotal Phase 3 clinical trial evaluating bomedemstat, an investigational orally available lysine-specific demethylase 1 inhibitor, for the treatment of patients with essential thrombocythemia [...]

Published
2024

13. Merck reports 'positive' results from Phase 2b/3 trial of clesrovimab

Subjects
Merck & Company Inc. -- Product development, Contraceptives industry -- Product development, Clinical trials, Monoclonal antibodies, Business, News, opinion and commentary
Abstract

Merck announced positive topline results from its Phase 2b/3 clinical trial evaluating clesrovimab (MK-1654), the company's investigational prophylactic monoclonal antibody designed to protect infants from respiratory syncytial virus disease. In [...]

Published
2024

14. Reports on Uveitis Findings from University of Bielefeld Provide New Insights (Low Uveitis Rates In Patients With Axial Spondyloarthritis Treated With Bimekizumab: Pooled Results From Phase 2b/3 Trials)

Subjects
Merck & Company Inc. -- Product development, Pfizer Inc. -- Product development, Novartis AG -- Product development, Eli Lilly and Co. -- Product development, UCB Pharma S.A. -- Product development, Celgene Corp. -- Product development, Uveitis -- Care and treatment -- Research, Physical fitness -- Research, Pharmaceutical industry -- Product development, Health
Abstract

2024 JUL 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on Eye Diseases and Conditions - Uveitis are discussed in [...]

Published
2024

15. Immtech's efti and Merck's Keytruda combination show positive Phase 2b results

Subjects
Merck & Company Inc. -- Product development, Squamous cell carcinoma, Clinical trials, Pharmaceutical industry -- Product development, Business, News, opinion and commentary, Keytruda (Medication) -- Product development
Abstract

Immutep (IMM) announced positive results from Cohort B of the TACTI-003 Phase IIb trial evaluating eftilagimod alfa - efti - in combination with Merck's (MRK) anti-PD-1 therapy Keytruda - pembrolizumab [...]

Published
2024

16. HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial

Author

Li, Zheqi, Filho, Otto Metzger, Viale, Giuseppe, dell'Orto, Patrizia, Russo, Leila, Goyette, Marie-Anne, Kamat, Avni, Yardley, Denise A., Abramson, Vandana Gupta, Arteaga, Carlos L., Spring, Laura M., Chiotti, Kami, Halsey, Carol, Waks, Adrienne G., King, Tari A., Lester, Susan C., Bellon, Jennifer R., Winer, Eric P., Spellman, Paul T., Krop, Ian E., and Polyak, Kornelia

Subjects
Merck & Company Inc. -- Product development, Genentech Inc. -- Product development, Novartis AG -- Product development, Agilent Technologies Inc. -- Product development, AstraZeneca PLC -- Product development, Eli Lilly and Co. -- Product development, RNA sequencing, Biotechnology industry -- Product development, Pertuzumab, B cells, RNA, Clinical trials, Instrument industry -- Product development, Breast cancer, Pharmaceutical industry -- Product development, Health care industry
Abstract

BACKGROUND. HER2-targeting therapies have great efficacy in HER2-positive breast cancer, but resistance, in part due to HER2 heterogeneity (HET), is a significant clinical challenge. We previously described that in a phase II neoadjuvant trastuzumab emtansine (T-DM1) and pertuzumab (P) clinical trial in early-stage HER2-positive breast cancer, none of the patients with HER2-HET tumors had pathologic complete response (pCR). METHODS. To investigate cellular and molecular differences among tumors according to HER2 heterogeneity and pCR, we performed RNA sequencing and ERBB2 FISH of 285 pretreatment and posttreatment tumors from 129 patients in this T-DM1+P neoadjuvant trial. A subset of cases was also subject to NanoString spatial digital profiling. RESULTS. Pretreatment tumors from patients with pCR had the highest level of ERBB2 mRNA and ERBB signaling. HER2 heterogeneity was associated with no pCR, basal-like features, and low ERBB2 expression yet high ERBB signaling sustained by activation of downstream pathway components. Residual tumors showed decreased HER2 protein levels and ERBB2 copy number heterogeneity and increased PI3K pathway enrichment and luminal features. HET tumors showed minimal treatment-induced transcriptomic changes compared with non-HET tumors. Immune infiltration correlated with pCR and HER2-HET status. CONCLUSION. Resistance mechanisms in HET and non-HET tumors are distinct. HER2-targeting antibodies have limited efficacy in HET tumors. Our results support the stratification of patients based on HET status and the use of agents that target downstream components of the ERBB signaling pathway in patients with HET tumors. TRIAL REGISTRATION. ClinicalTrials.gov NCT02326974. FUNDING. This study was funded by Roche and the National Cancer Institute., Introduction Breast cancer is one of the most prevalent and life-threatening malignancies in women worldwide (1). Breast cancer is a heterogeneous disease clinically classified on the basis of the expression [...]

Published
2024
Full Text
View/download PDF

17. Eli Lilly presents updated data from Phase 1/2 study of Olomorasib

Subjects
Merck & Company Inc. -- Product development, Eli Lilly and Co. -- Product development, Clinical trials, Lung cancer, Non-small cell, Pharmaceutical industry -- Product development, Business, News, opinion and commentary
Abstract

Eli Lilly announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in patients with KRAS G12C-mutant advanced solid tumors and in combination with Merck's anti-PD-1 [...]

Published
2024

18. Merck discontinues vibostolimab-Keytruda combination arm of Phase 3 trial

Subjects
Merck & Company Inc. -- Product development, Pharmaceutical industry -- Product development, Business, News, opinion and commentary, Keytruda (Medication) -- Product development
Abstract

Merck announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the Phase 3 KeyVibe-010 trial. The trial is evaluating the investigational coformulation of vibostolimab, an anti-TIGIT antibody, and [...]

Published
2024

19. Wedbush upgrades CytomX to Outperform on 'encouraging' CX-904 Phase 1a data

Subjects
Merck & Company Inc. -- Product development, Pancreatic cancer, Pharmaceutical industry -- Product development, Business, News, opinion and commentary
Abstract

As previously reported, Wedbush upgraded CytomX Therapeutics (CTMX) to Outperform from Neutral with an $8 price target. The firm notes CytomX shared initial dose-escalation data for its masked EGFR x [...]

Published
2024

20. CytomX Therapeutics, Merck enter CX-801 trial collaboration

Subjects
Merck & Company Inc. -- Product development, Medical research, Medicine, Experimental, Pharmaceutical industry -- Product development, Business, News, opinion and commentary
Abstract

CytomX Therapeutics (CTMX) announced that it has entered into a clinical trial collaboration and supply agreement with Merck (MRK) for CytomX's first-in-human Phase 1 clinical trial assessing the clinical activity [...]

Published
2024

21. Merck initiates Phase 3 clinical trial of MK-1084

Subjects
Merck & Company Inc. -- Product development, Clinical trials, Lung cancer, Non-small cell, Pharmaceutical industry -- Product development, Business, News, opinion and commentary, Keytruda (Medication) -- Product development
Abstract

Merck announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA for the first-line treatment of certain patients [...]

Published
2024

22. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough

Author

McGarvey, Lorcan, Smith, Jaclyn A., Morice, Alyn, Birring, Surinder S., Chung, Kian Fan, Dicpinigaitis, Peter V., and Niimi, Akio

Subjects
Merck & Company Inc. -- Product development, Shionogi & Company Ltd. -- Product development, Bayer AG -- Product development, Medical research, Medicine, Experimental, Patient compliance -- Research, Clinical trials -- Research, Pharmaceutical industry -- Product development, Health, Cleveland Clinic
Abstract

Introduction To determine the optimal dose of sivopixant, a highly selective P2X3 receptor antagonist, for refractory or unexplained chronic cough (RCC/UCC). Methods In this phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial, patients received sivopixant 50, 150, or 300 mg or placebo once daily for 4 weeks. The primary endpoint was a change from baseline in 24-h cough frequency (coughs/h) with sivopixant vs placebo. Results Overall, 390/406 randomized patients completed the study. Placebo-adjusted changes in hourly cough count over 24 h were 13.17% (P = 0.3532), - 1.77% (P = 0.8935), and - 12.47% (P = 0.3241) and in cough severity (visual analog scale) were 1.75 mm (P = 0.5854), - 1.21 mm (P = 0.7056), and - 6.55 mm (P = 0.0433) with sivopixant 50, 150, and 300 mg, respectively. Placebo-adjusted changes from baseline in Leicester Cough Questionnaire total scores were - 0.37 (P = 0.4207), - 0.07 (P = 0.8806), and 0.69 (P = 0.1473) with sivopixant 50, 150, and 300 mg, respectively. Additionally, 61.3%, 78.3%, 86.8%, and 71.4% of patients receiving sivopixant 50, 150, and 300 mg and placebo, respectively, reported any improvements in Patient Global Impression of Change. The incidence of treatment-emergent adverse events (TEAEs) was 25.7%, 32.0%, 49.0%, and 20.6% in sivopixant 50, 150, and 300 mg and placebo groups, respectively; all TEAEs in the sivopixant group were mild-to-moderate. Conclusion Sivopixant did not demonstrate a statistically significant difference vs placebo in change from baseline in 24-h cough frequency. The dose of 300 mg has potential for RCC/UCC, showing the greatest improvements in cough frequency and patient-reported outcomes and dose-related mild to moderate reversible taste disturbance, although further trials are needed. Clinical Trial Registration ClinicalTrials.gov identifier NCT04110054; registered September 26, 2019., Author(s): Lorcan McGarvey [sup.1], Jaclyn A. Smith [sup.2], Alyn Morice [sup.3], Surinder S. Birring [sup.4], Kian Fan Chung [sup.5], Peter V. Dicpinigaitis [sup.6], Akio Niimi [sup.7], Michael S. Benninger [sup.8], [...]

Published
2023
Full Text
View/download PDF

23. LYNPARZA(r) (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial

Subjects
Merck & Company Inc. -- Product development, AstraZeneca PLC -- Product development, Breast cancer, General interest, News, opinion and commentary, Lynparza (Medication) -- Product development
Abstract

RAHWAY: MERCK & CO., INC has issued the following news release: AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term results [...]

Published
2024

24. Merck's Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma

Subjects
Merck & Company Inc. -- Product development, Care and treatment, Product development, Non-Hodgkin lymphomas -- Care and treatment, Cogeneration power plants -- Product development, Biological products -- Product development, Non-Hodgkin's lymphomas -- Care and treatment
Abstract

Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate RAHWAY, N.J. -- Merck (NYSE: MRK), known as MSD outside of [...]

Published
2024

25. Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIOtm (molnupiravir) for the Treatment of COVID-19 in High-Risk Adults

Subjects
Merck & Company Inc. -- Product development, Lagevrio (Medication) -- Product development, Care and treatment, Development and progression, Product development, Clinical trials, Antiviral agents -- Product development, COVID-19 -- Care and treatment -- Development and progression, Adults
Abstract

RAHWAY: Merck & Co., Inc. has issued the following news release: Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the [...]

Published
2024

26. Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints

Subjects
Merck & Company Inc. -- Product development, Metastasis, Axitinib, Pemetrexed -- Product development, Lung cancer, Non-small cell, Chemotherapy, Cancer -- Chemotherapy, Pharmaceutical industry -- Product development, Business, Business, international, Keytruda (Medication) -- Product development
Abstract

Investigational subcutaneous pembrolizumab and berahyaluronidase alfa, in combination with chemotherapy, demonstrates noninferior pharmacokinetics compared to intravenous KEYTRUDA in combination with chemotherapy in adults with metastatic non-small cell lung cancer Merck [...]

Published
2024

27. Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial

Subjects
Merck & Company Inc. -- Product development, Tumors -- Care and treatment -- Research -- Patient outcomes, Clinical trials -- Research, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

SHANGHAI: Abbisko has issued the following news release: Abbisko today announced that the Phase 3 MANEUVER study evaluating pimicotinib in the treatment of tenosynovial giant cell tumor (TGCT) achieved statistically [...]

Published
2024

28. KOSELUGO[R] (selumetinib) Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults With Neurofibromatosis Type 1 who Have Symptomatic, Inoperable Plexiform Neurofibromas in Global Phase 3 KOMET Trial

Subjects
Merck & Company Inc. -- Product development, AstraZeneca PLC -- Product development, Neurofibromatosis -- Complications and side effects -- Research, Clinical trials -- Research, Pharmaceutical industry -- Product development, Business, Business, international, Koselugo (Medication) -- Product development -- Complications and side effects -- Research
Abstract

These results showed reduction in tumor volume, building on the established safety and efficacy profile of KOSELUGO in certain children and has the potential to support expanded use in certain [...]

Published
2024

29. Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA[R] (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)

Subjects
United States. Securities and Exchange Commission -- Evaluation, Merck & Company Inc. -- Product development, Moderna Inc. -- Product development, Biotechnology industry -- Product development, Axitinib -- Complications and side effects, Messenger RNA, Pemetrexed -- Evaluation -- Product development -- Complications and side effects, Chemotherapy, Lung cancer, Non-small cell -- Care and treatment -- Complications and side effects, Clinical trials, Cancer -- Chemotherapy, Tumor antigens, Pharmaceutical industry -- Product development, Business, Business, international, Keytruda (Medication) -- Evaluation
Abstract

The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program, as the third Phase 3 trial for the investigational individualized neoantigen therapy, V940 (mRNA-4157), focused on earlier stages [...]

Published
2024

30. Advanced Renal Cell Carcinoma Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Molecure S.A., Daiichi Sankyo, Janux Therapeutics

Subjects
Merck & Company Inc. -- Product development, Infinity Pharmaceuticals -- Product development, Biological products industry -- Product development, Axitinib -- Reports, Cancer -- Care and treatment, Clinical trials -- Reports, Carcinoma, Renal cell -- Reports, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-October 24, 2024-: Advanced Renal Cell Carcinoma Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Molecure S.A., Daiichi Sankyo, Janux Therapeutics (C)1994-2024 [...]

Published
2024

31. Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Subjects
Merck & Company Inc. -- Product development, Gilead Sciences Inc. -- Product development, Biological products industry -- Product development, HIV (Viruses) -- Drug therapy, Clinical trials, Adults, AIDS treatment, Dofetilide -- Product development, Emtricitabine -- Product development, Pharmaceutical industry -- Product development, DNA polymerases, Business, Business, international, Biktarvy (Medication) -- Product development
Abstract

- Novel Investigational Combination Regimen is Advancing to Phase 3 and has the Potential to Become the First Weekly Oral HIV Treatment - FOSTER CITY, Calif., & RAHWAY, N.J. -- [...]

Published
2024

32. Merck's Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants

Subjects
Merck & Company Inc. -- Product development, Palivizumab -- Product development -- Complications and side effects, Respiratory tract diseases -- Complications and side effects, Infants, Infection -- Complications and side effects, Contraceptives industry -- Product development, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

In the Phase 2b/3 trial, clesrovimab reduced RSV-associated hospitalizations (secondary endpoint) and RSV-associated lower respiratory infection hospitalizations (tertiary endpoint) by more than 84% and 90%, respectively, through 5 months Clesrovimab [...]

Published
2024

33. Cholangiocarcinoma Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, MOA, ROA, and Companies by DelveInsight | Merck, Eisai, Janssen Research, 3D Medicines

Subjects
Merck & Company Inc. -- Product development, AstraZeneca PLC -- Product development, Eisai Company Ltd. -- Product development, Medical research -- Reports, Medicine, Experimental -- Reports, Business -- Research, Drugs -- Product development, Clinical trials -- Reports, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-October 8, 2024-: Cholangiocarcinoma Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, MOA, ROA, and Companies by DelveInsight | Merck, Eisai, Janssen Research, 3D Medicines (C)1994-2024 M2 COMMUNICATIONS [...]

Published
2024

34. Merck initiates Phase 3 trial for LAGEVRIO (molnupiravir)

Subjects
Merck & Company Inc. -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Business, Lagevrio (Medication) -- Product development
Abstract

M2 EQUITYBITES-December 5, 2024-Merck initiates Phase 3 trial for LAGEVRIO (molnupiravir) (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and [...]

Published
2024

35. Merck initiates Phase 3 trial for LAGEVRIO (molnupiravir)

Subjects
Merck & Company Inc. -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Chemistry, Lagevrio (Medication) -- Product development
Abstract

M2 PHARMA-December 5, 2024-Merck initiates Phase 3 trial for LAGEVRIO (molnupiravir) (C)2024 M2 COMMUNICATIONS US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, [...]

Published
2024

36. Merck reports positive Phase 3 ZENITH results for WINREVAIR in PAH treatment

Subjects
Merck & Company Inc. -- Product development, Pulmonary hypertension, Chemistry, Winrevair (Medication) -- Product development
Abstract

M2 PHARMA-November 25, 2024-Merck reports positive Phase 3 ZENITH results for WINREVAIR in PAH treatment (C)2024 M2 COMMUNICATIONS Biopharmaceutical company Merck (NYSE: MRK) announced on Monday that its Phase 3 [...]

Published
2024

37. Merck reports positive Phase 3 ZENITH results for WINREVAIR in PAH treatment

Subjects
Merck & Company Inc. -- Product development, Pulmonary hypertension, Business, Winrevair (Medication) -- Product development
Abstract

M2 EQUITYBITES-November 25, 2024-Merck reports positive Phase 3 ZENITH results for WINREVAIR in PAH treatment (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Biopharmaceutical company Merck (NYSE: MRK) announced on Monday that its Phase [...]

Published
2024

38. ABL Bio signs clinical trial collaboration and supply agreement with MSD

Subjects
Merck & Company Inc. -- Product development, Keytruda (Medication) -- Product development, Product development, Clinical trials, Medical research, Pembrolizumab, Pharmaceutical industry -- Product development, Medicine, Experimental
Abstract

M2 PHARMA-October 4, 2024-ABL Bio signs clinical trial collaboration and supply agreement with MSD (C)2024 M2 COMMUNICATIONS Biotech company ABL Bio announced on Friday that it has signed a clinical [...]

Published
2024

39. ABL Bio signs clinical trial collaboration and supply agreement with MSD

Subjects
Merck & Company Inc. -- Product development, Keytruda (Medication) -- Product development, Product development, Clinical trials, Medical research, Pembrolizumab, Pharmaceutical industry -- Product development, Medicine, Experimental
Abstract

M2 EQUITYBITES-October 4, 2024-ABL Bio signs clinical trial collaboration and supply agreement with MSD (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Biotech company ABL Bio announced on Friday that it has signed a [...]

Published
2024

40. DHT RAMP-UP: PHARMA STEPS UP PURSUITS IN DIGITAL TECHNOLOGY

Subjects
Merck & Company Inc. -- Product development, McKinsey and Company Inc. -- Product development, Pfizer Inc. -- Product development, AstraZeneca PLC -- Product development, Sanofi S.A. -- Product development, Consulting services -- Product development, Pharmaceutical industry -- Product development, General interest, Health
Abstract

Christine Bahls Freelance Writer for Medical, Clinical Trials, and Pharma Information In the recent past, most Big Pharma companies used digital heath technology (DHT) on a project-by-project basis, or perhaps [...]

Published
2024

41. Biliary Tract Cancer Pipeline Analysis 2024: FDA Approvals and Emerging Therapies, MOA, ROA by DelveInsight | Agios Pharma, Servier Pharma, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Incyte Crp

Subjects
Merck & Company Inc. -- Product development, AstraZeneca PLC -- Product development, Medical research -- Reports, Medicine, Experimental -- Reports, Cancer -- Care and treatment, Clinical trials -- Reports, Pharmaceutical industry -- Product development, Business, Business, international, Imfinzi (Medication) -- Reports -- Product development
Abstract

M2 PRESSWIRE-September 25, 2024-: Biliary Tract Cancer Pipeline Analysis 2024: FDA Approvals and Emerging Therapies, MOA, ROA by DelveInsight | Agios Pharma, Servier Pharma, Merck Sharp & Dohme, AstraZeneca, Taiho [...]

Published
2024

42. Head and Neck Cancer Clinical Trials, Pipeline Insights, Treatment Drugs, and Companies 2024

Subjects
Merck & Company Inc. -- Product development, Business -- Research, Clinical trials -- Reports, Pharmaceutical industry -- Product development, Head and neck cancer -- Reports, Business, Business, international
Abstract

M2 PRESSWIRE-September 20, 2024-: Head and Neck Cancer Clinical Trials, Pipeline Insights, Treatment Drugs, and Companies 2024 (C)1994-2024 M2 COMMUNICATIONS RDATE:19092024 DelveInsight's, 'Head and Neck Cancer Pipeline Insight 2024' report [...]

Published
2024

43. Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial

Subjects
Merck & Company Inc. -- Product development, Tyrosine -- Product development, Metastasis -- Care and treatment -- Patient outcomes, Lung cancer, Small cell -- Patient outcomes -- Care and treatment, Pemetrexed -- Product development, Chemotherapy, Lung cancer, Non-small cell -- Care and treatment -- Patient outcomes, Cancer -- Chemotherapy, Business, Business, international
Abstract

* Daiichi Sankyo and Merck's patritumab deruxtecan demonstrates a statistically significant progression-free survival improvement in this EGFR-mutated non-small cell lung cancer population with high unmet need following prior EGFR TKI [...]

Published
2024

45. Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL[R]9 in Japanese Males

Subjects
Merck & Company Inc. -- Product development, Papillomavirus infections, Clinical trials, Vaccines -- Product development -- Evaluation, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

RAHWAY, N.J. -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive top-line results from its pivotal Phase 3 trial (V503-064) evaluating the [...]

Published
2024

46. IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA(r) (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

Subjects
Merck & Company Inc. -- Product development, Biotechnology, Clinical trials, Cancer vaccines -- Product development, Melanoma -- Care and treatment, General interest, News, opinion and commentary, Keytruda (Medication) -- Product development
Abstract

NEW YORK: IO Biotech has issued the following news release: IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win(r) platform, [...]

Published
2024

47. Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombocythemia

Subjects
Merck & Company Inc. -- Product development, Clinical trials, Pharmaceutical industry -- Product development, News, opinion and commentary
Abstract

RAHWAY, N.J.--(BUSINESS WIRE)--Aug 27, 2024-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of Shorespan-007, a pivotal Phase 3 clinical trial [...]

Published
2024

48. Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombocythemia

Subjects
Merck & Company Inc. -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company's commitment to advancing research in myeloproliferative neoplasms (MPNs) RAHWAY, N.J. -- Merck (NYSE: MRK), known as MSD [...]

Published
2024

49. TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

Subjects
Keytruda (Medication) -- Evaluation, Cancer patients, Immunotherapy, Cancer -- Care and treatment, Clinical trials, Pharmaceutical industry -- Product development, Merck & Company Inc. -- Product development
Abstract

30 of a projected 39 patients have been enrolled in the clinical trial to date, including a monotherapy arm with KVA12123 and a combination arm utilizing KVA12123 together with Merck's [...]

Published
2024

50. IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer

Subjects
Merck & Company Inc. -- Product development, Biological products -- Product development, Lung cancer, Small cell -- Care and treatment, Chemotherapy, Cancer -- Chemotherapy, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

BASKING RIDGE, N.J. & RAHWAY, N.J. -- Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the first [...]

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results